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PERFORM-K was a cross-sectional observational study that investigated functional disability, productivity
and quality of life in MDD outpatients in South Korea, and the associations of these with depressive
symptoms, perceived cognitive dysfunction and other factors. A total of 312 outpatients who started
antidepressant monotherapy underwent a single study interview. Physicians and patients assessed de-
pression severity. Patients also assessed: perceived cognitive dysfunction, functional disability, impaired
productivity and quality of life. Patients had moderate to severe depression (MADRS mean total score:
28.977.3), and reported marked functional disability (SDS mean total score: 16.778.6), impaired pro-
ductivity (WPAI mean overall work productivity loss: 52.4731.8%), perceived cognitive dysfunction
(PDQ-D mean total score: 29.9718.6) and impaired quality of life (EQ-5D mean utility index score of
0.72670.192). Greater functional disability and impairment in daily activities were associated with more
severe depression and greater perceived cognitive dysfunction. Irrespective of depression severity, pa-
tients with more severe perceived cognitive dysfunction reported worse work-related productivity
outcomes (higher presenteeism and greater overall work productivity loss). PERFORM-K conﬁrms the
impact of MDD on functional status and well-being in South Korean patients, and highlights the im-
portance of recognising cognitive dysfunction in clinical practice.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Depressive disorders including major depressive disorder
(MDD) have consistently been reported as being amongst the
leading causes of disability worldwide in the Global Burden of
Disease studies by the World Health Organisation (Ferrari et al.,
2013). The average lifetime prevalence of MDD is estimated at
14.6% for high income countries (Kessler and Bromet, 2013); in
South Korea, the lifetime prevalence is estimated at 6.7%, which
has increased by 0.2% annually over the past decade (Jeon, 2012).
MDD is characterized by physical, cognitive and emotional
symptoms that affect patient functioning and quality of life
(Hammar and Ardal, 2009; Langlieb and Guico-Pabia, 2010; FerrariIreland Ltd. This is an open acces
101 Thomson Road, #13-05et al., 2013). Several studies have identiﬁed an association between
depression severity and functional impairment (Kennedy et al.,
2002; Srisurapanont et al., 2013), and report the long-term nega-
tive impact of depression on work performance, social adjustment,
engagement in leisure activities and family relationships (Tweed,
1993; Kennedy and Paykel, 2004; Greer et al., 2010; Conradi et al.,
2011). Apart from the emotional burden, the loss of work pro-
ductivity and impaired work performance associated with MDD re-
sult in a substantial economic burden – in 2005, the total cost of
depression in South Korea was estimated at $4.05 billion, with in-
direct costs attributable to lost workplace productivity ($2.96 billion)
far exceeding medical costs ($152.6 million) (Chang et al., 2012).
Cognitive dysfunction is gaining attention as one of the key
determinants of functional disability in MDD patients (Hammar
and Ardal, 2009; Conradi et al., 2011; McIntyre et al., 2013). In
MDD, the most commonly impaired cognitive domains are: at-
tention, memory, executive function and processing speed (Millan
et al., 2012). Some cognitive dysfunction may persist beyonds article under the CC BY-NC-ND license
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suggested to impact work function and lead to poor occupational
outcomes (Adler et al., 2006; Israel, 2006). With increased re-
cognition of the debilitating impact of MDD symptoms on patient
functioning, the goal of MDD treatment now goes beyond
achieving clinical remission to include recovery of functional sta-
tus (Greer et al., 2010).
Several studies have investigated the burden of MDD in South
Korea and described the impact of depression on patients' ability
to work, lost productive time and their quality of life (Kim et al.,
2011; Woo et al., 2011; Oh et al., 2013; Sohn et al., 2013). However,
no study has to date been conducted to speciﬁcally examine the
impact of cognitive symptoms of MDD patients on their functional
disability and work impairment in South Korea. The objective of
this study was to investigate the functional disability, work pro-
ductivity and quality of life of MDD outpatients in South Korea,
and the association with depressive symptoms, perceived cogni-
tive dysfunction and other factors.2. Methods
PERFORM-K (Epidemiological Research on Functioning Out-
comes Related to Major depressive disorder in South Korea) was
an observational, cross-sectional, multi-site study.
2.1. Study participants
Patients were recruited from 29 psychiatric departments in
university or general hospitals throughout South Korea from Oc-
tober 2013 to January 2014. Eligible patients were outpatients
between 19 and 65 years old with a diagnosis of MDD according to
the DSM-IV, conﬁrmed by the Mini-International Neuropsychiatric
Interview (Sheehan et al., 1998), and started on antidepressant
monotherapy either as ﬁrst-line therapy or as ﬁrst treatment
switch from previous antidepressant monotherapy. Patients were
excluded if they: had a diagnosis of bipolar disorder, schizophrenia
or other psychotic disorder, substance dependence, dementia or
other neurodegenerative diseases that affect cognitive functioning,
or a mood disorder due to general medical conditions or sub-
stances; were acutely suicidal; were pregnant, breastfeeding or
6 months post-partum; were unable to read or understand the
information sheet, informed consent form or patient-reported
questionnaires; or were concurrently participating in another
clinical trial. Based on the above inclusion and exclusion criteria,
patients attending psychiatric departments of the study hospitals
were recruited consecutively if they agreed to participate.
Antidepressant treatment was not determined in advance by
the study protocol and treatment was clearly separated from the
decision to include the patient in the study. All eligible patients
had given written informed consent. The study was approved by
the institutional review boards of all participating hospitals.
2.2. Study design and study assessments
Study participants underwent a single interview during a
routine visit by the patient in the normal course of care when a
new antidepressant was initiated as monotherapy. Patient in-
formation collected during the study visit included socio-demo-
graphic data, physical characteristics and past medical history.
Depression severity was measured using both physician-rated
assessments and patient-reported outcome (PRO) instruments.
Physicians assessed depression severity using the Clinical Global
Impressions – Severity of Illness scale (CGI-S) and the Mon-
tgomery-Åsberg Depression Rating Scale (MADRS). CGI-S is a
standardised, generic assessment tool for rating the severity of anillness on a 7-point scale (with 1 indicating normal health and
7 indicating extreme illness) (Guy, 1976). The MADRS consists of
10 items, with each item rated from 0 (normal ﬁndings or absence
of symptoms) to 6 (severe depressive symptoms) adding up to a
total score of 60 (Montgomery and Asberg, 1979). The following
pre-deﬁned MADRS categories often used in clinical trials (Raison
et al., 2007; Bose et al., 2012) and considered to be representative
of depression severity were used in this study: “in remission or
mild depression” (0–25), “moderate depression” (26–29), “severe
depression” (30–34) and “very severe depression” (35–60). Pa-
tients also assessed depression severity using the 9-item Patient
Health Questionnaire (PHQ-9) (Kroenke et al., 2001). A total score
ranging from 0 (absence of depression) to 27 (severe depression) is
calculated, with depression severity categorised as “in remission”
(total score r4), “minimal symptoms” (5–9), “mild depression”
(10–14), “moderately severe depression” (15–19) and “severe de-
pression” (20–27).
Cognitive dysfunction was assessed using the Perceived Deﬁcits
Questionnaire for Depression (PDQ-D) (Sullivan et al., 1990). The
self-reported, 20-item instrument assesses four sub-scales: at-
tention/concentration, retrospective memory, prospective mem-
ory and planning/organisation. Each item is rated on a 0–4 scale,
with a total score of 20 for each of the sub-scales. As there is no
known threshold to deﬁne severity of perceived cognitive dys-
function, categories were deﬁned as distribution-based quartiles
with higher scores indicating worse perceived cognitive
dysfunction.
In our study ‘functioning outcomes’ referred to functional dis-
ability and work- or activity-related productivity. The Sheehan
Disability Scale (SDS) was used to assess functional disability over
the previous 7 days in 3 domains: work/school, social life/leisure
activities and family life/home duties (Sheehan et al., 1996). Pa-
tients rated the severity of impairment in each domain on a scale
of 0–10; a total functional impairment score was computed ran-
ging from 0 (unimpaired) to 30 (highly impaired). “Marked dis-
ruption” was deﬁned as an SDS score of at least 7 in a domain.
The Work Productivity and Activity Impairment, Speciﬁc Health
Problems questionnaire (WPAI) is a self-administered instrument
that was used to measure impairment in productivity related to
work and regular, daily activities (such as household work, child-
care, shopping, exercising or studying) (Reilly et al., 1993). Pro-
ductivity is assessed on a 10-point scale with higher scores in-
dicative of worse work productivity or activity impairment. Scores
are multiplied by 100 and reported in the following indexes: ab-
senteeism (percent of work time missed due to MDD), pre-
senteeism (percent impairment while working due to MDD),
overall work productivity loss (a composite measure of both pre-
senteeism and absenteeism) and activity impairment (degree of
impairment of regular, non-work activities due to MDD).
Quality of life was measured by the EuroQOL Five Dimensions
(EQ-5D) questionnaire. Patients rated severity levels (“no pro-
blems”, “some problems” or “extreme problems”) for each of the
ﬁve health dimensions (mobility, self-care, usual activities, pain/
discomfort and depression/anxiety). A utility index score was de-
rived, wherein “1” indicated perfect health, “0” indicated a state of
death and scores below 0 indicated a state worse than death. Pa-
tients also assessed their health state with a visual analogue scale
that ranged between 0 (worst imaginable health state) and 100
(best imaginable health state) (EuroQol Group, 1990).
2.3. Statistical analysis
The population for analysis comprised all eligible patients who
completed at least one of the PRO assessments. All assessment
data were summarised from the single study visit using de-
scriptive techniques. Unless otherwise speciﬁed, continuous
Fig. 1. Patient ﬂowchart.
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mean7standard deviation (SD); categorical and binary variables
are presented as counts and percentages.
Functional disability (mean total SDS score), productivity (WPAI
mean sub-scores) and quality of life (EQ-5D mean utility index
score) were compared between patient groups deﬁned by de-
pression severity (MADRS) and severity of perceived cognitive
dysfunction (PDQ-D).
MADRS items were compared between patient groups deﬁned
by severity of perceived cognitive dysfunction (PDQ-D) using one-
way analyses of variance (ANOVA).1 Correlations between MADRS
and PDQ-D were calculated using Pearson's and Spearman's cor-
relation coefﬁcients.
To determine factors associated with functional disability
(SDS), productivity (WPAI) and quality of life (EQ-5D), a two-step
statistical analysis was performed. SDS total score, WPAI sub-
scores and EQ-5D utility index score were compared between
patient groups by means of one-way ANOVA.2 SDS total score,
WPAI sub-scores and EQ-5D utility index score were then each
evaluated using analyses of co-variance (ANCOVA) with region,
age, gender and MADRS categories as forced factors and the fol-
lowing as co-factors and covariates (added to the model if their
p-value was lower than 0.10 in the univariate analyses): educa-
tional level, presence of anxiety symptom or disorder, presence of
chronic medical condition, presence of chronic pain or ﬁ-
bromyalgia, recurrence of depression episode, time of previous
depression episode, history of suicide attempt, history of sick leave
in the previous 12 months, history of hospitalisation, time since
beginning of current major depressive episode, switch of treat-
ment at study inclusion, depression severity as assessed by CGI-S
and severity of perceived cognitive dysfunction as assessed by
PDQ-D. Statistical tests were two-sided at a 5% signiﬁcance level.
Imputation of missing data was not used in any of the analyses
(i.e. all data were observed cases). Analyses were performed using
the SASs statistical software (SAS Institute, Cary, NC, USA), Version
9.2.3. Results
The study enroled 343 patients, 31 of whom were excluded
from the analyzable population (Fig. 1).
3.1. Demographic data and clinical characteristics
Patients had a mean age of 45.2713.1 years, most were women
(74.0%), had received formal education until at least high school
(73.1%), and generally lived in urban areas of South Korea (83.3%).
Similar proportions of patients were employed or not employed
(41.7% versus 38.5%, respectively); the remaining patients com-
prised a non-working population that included students and re-
tirees (Table 1).
The majority of patients were newly diagnosed with MDD1 MADRS items included: apparent sadness, reported sadness, inner tension,
reduced sleep, reduced appetite, concentration difﬁculties, lassitude, inability to
feel, pessimistic thoughts and suicidal thoughts.
2 Patient groups were deﬁned by the following variables: region, age, gender,
educational level, presence of anxiety symptom or disorder, presence of chronic
medical condition, presence of chronic pain or ﬁbromyalgia, presence of sleep
disorders, recurrence of depression episode, history of sick leave in the past 12
months, history of hospitalisation, history of suicide attempt, time of previous
depressive episode, time since beginning of this depressive episode, switch of
treatment at study inclusion, severity of depression as assessed by PHQ-9, MADRS
and CGI-S, and severity of perceived cognitive dysfunction as assessed by PDQ-D.
Additional variables considered in the analysis of EQ-5D were: presence of an
important family event and presence of an important professional event.(59.6%). Over half of the patients (55.4%) presented with clinically
signiﬁcant symptoms of anxiety. Antidepressant treatment was
initiated as ﬁrst-line monotherapy in 77.2% of patients at the study
visit, while the remaining 22.8% of patients (n¼71) had previously
been treated with an antidepressant and were switching therapy.
The main reason for switching treatment was lack of efﬁcacy of
the previous antidepressant therapy (78.6%) (Table 1).
Patients were rated by physicians as having moderate to severe
depression, with a MADRS mean total score of 28.977.3. Patients'
self-reported levels of depression severity were consistent with
physician-rated levels of depression severity, with 62.3% reporting
a PHQ-9 score between 15 and 27 (moderate to severe
depression).
Although there are no pre-deﬁned categories for the severity of
perceived cognitive dysfunction, patients reported a PDQ-D mean
total score of 29.9718.6, which fell in the third quartile of the
PDQ-D score distribution (ﬁrst quartile: 0–12; second quartile: 13–
27; third quartile: 28–43; fourth quartile: 44–80) (Table 1). PDQ-D
scores for the individual dimensions were: 8.575.3 for attention/
concentration, 6.175.1 for retrospective memory, 6.474.6 for
prospective memory and 8.975.6 for planning/organisation.
All items in the MADRS were signiﬁcantly associated with more
severe perceived cognitive dysfunction (p¼0.004 for “reduced
appetite”; po0.001 for all other MADRS items), except “reduced
sleep” (p¼0.394). Pearson and Spearman correlation coefﬁcients
between MADRS and PDQ-D scores were 0.41 and 0.42
respectively.
3.2. Functioning outcomes and quality of life
Patients reported the following mean SDS scores in the re-
spective domains: 5.773.2 for work/school, 5.673.1 for family
life/home duties and 5.473.3 for social life/leisure activities. A
similar proportion of patients reported ‘marked disruption’ across
all three SDS domains (Table 2). Higher levels of functional dis-
ability (deﬁned by SDS) were reported in patients with more se-
vere depression (Fig. 2a) and those with more severe perceived
cognitive dysfunction (Fig. 2b).
Table 1
Socio-demographics and clinical characteristics.
n Values
Age (mean years7SD) 312 45.2713.1
Gender 312
Male 81 (26.0%)
Female 231 (74.0%)
Highest educational level 312
No degree or diploma 6 (1.9%)
Elementary school 25 (8.0%)
Middle school 53 (17.0%)
High school 114 (36.5%)
Non-university degree 30 (9.6%)
University degree 84 (26.9%)
Living area 305
Rural 51 (16.7%)
Urban 254 (83.3%)
Employment status 312f
Employeda 130 (41.7%)
Unemployed 120 (38.5%)
Non-working 63 (20.2%)
MDD history and treatment
Current episode is ﬁrst MDE 312 186 (59.6%)
Time since beginning of this episode 312
o8 weeks 107 (34.3%)
48 weeks 205 (65.7%)
History of previous hospitalisation for depression 126g 7 (5.6%)
Previous hospitalisation for any cause in past 12 weeks 312 36 (11.5%)
Sick leave in past 12 weeks 52h 42 (80.8%)
Current MDE already treated with an AD 312 71 (22.8%)
Primary reason for AD treatment switch 70i
Lack of efﬁcacy 55 (78.6%)
Adverse event 12 (17.1%)
Patient's decision 2 (2.9%)
Lack of compliance 1 (1.4%)
Current MDE treated with psychotherapy 312 34 (10.9%)
Medical history
Clinically signiﬁcant symptom of anxietyb or disorderc 312 173 (55.4%)
At least one chronic medical conditiond 312 104 (33.3%)
At least one functional syndromee 312 70 (22.4%)
CGI-S
Total score (mean7SD) 312 4.370.9
By categories
Normal to mildly ill (1–3) 52 (16.7%)
Moderately ill (4) 136 (43.6%)
Markedly ill to among the most extremely ill (5–7) 124 (39.7%)
MADRS
Total score (mean7SD) 312 28.977.3
By categories:
In remission or mild depression (0–25) 100 (32.1%)
Moderate depression (26–29) 59 (18.9%)
Severe depression (30–34) 75 (24.0%)
Very severe depression (35–60) 78 (25.0%)
PHQ-9
Total score (mean7SD) 310 16.076.5
By categories:
In remission (0–4) 16 (5.2%)
Minimal symptoms (5–9) 45 (14.5%)
Mild depression (10–14) 56 (18.1%)
Moderately severe depression (15–19) 90 (29.0%)
Severe depression (20–27) 103 (33.2%)
PDQ-D
Total score (mean7SD) 307 29.9718.6
Number of patients by quartiles:
First quartile (0–12) 69 (22.5%)
Second quartile (13–27) 84 (27.3%)
Third quartile (28–43) 77 (25.1%)
Fourth quartile (44–80) 77 (25.1%)
AD antidepressant; MDE major depressive episode.
a At least 32 h a week.
b Clinically signiﬁcant symptom of anxiety (panic, worrying, phobic fears,
avoidance, etc.).
c Anxiety disorder according to DSM-IV criteria (panic disorder, agoraphobia,
generalised anxiety disorder, social phobia, speciﬁc phobia, post-traumatic stress
disorder, obsessive compulsive disorder).
d Chronic medical condition (cardiovascular disease, diabetes, cancer, rheu-
matoid arthritis, neurologic disorders, others).
e Functional syndrome (chronic pain, chronic fatigue, ﬁbromyalgia, pre-
menstrual syndrome, sleep disorders, others).
f One patient responded “yes” to two options (the patient was a student and
employed part-time).
g Among patients whose current episode was not ﬁrst MDE (n¼126).
h Patients that had taken sick leave within the past 12 months (n¼52) were
then asked if they had taken sick leave within the past 12 weeks.
i Among patients already treated with an antidepressant at point of study in-
clusion (n¼71).
Table 2
Functional disability and productivity.
n Scorea
SDS
Work/school 302 5.773.2
Social life/leisure 312 5.473.3
Family/home life 312 5.673.1
Total 302 16.778.6
Median total (range) 302 18 (0–30)
WPAI
Percent work time missed due to problem (absenteeism) 97b 20.0733.5
Percent impairment while working (presenteeism) 94b 47.1730.5
Percent overall work impaired (overall work productivity
loss)
89b 52.4731.8
Percent activity impaired due to problem (activity
impairment)
307 57.9729.8
Hours missed from work due to MDD in previous 7 days 105b 9.6721.2
Hours worked in previous 7 days 110b 35.2730.3
EQ-5D
Mobility 312 1.370.6
Self-care 312 1.170.3
Usual activities 312 1.670.6
Pain/discomfort 312 1.970.6
Anxiety/depression 312 2.270.6
Utility index score 312 0.72670.192
Health state 310 50.8722.1
a All scores are presented as mean7SD, unless otherwise stated.
b WPAI sub-scales were only assessed in working patients, where “work” re-
ferred to paid work. It should be noted that the SDS “work/school” domain was
assessed in both working and non-working patients, where “work” included both
paid and non-paid work, such as housework, volunteer work or work done at
home.
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loss of 52.4% in the last 7 days, with 20% of work time missed
(absenteeism) and 47.1% of actual work impaired (presenteeism)
due to MDD (Table 2). Similarly, 57.9% of patients' regular, daily
activities were impaired due to MDD. Productivity as assessed by
each domain of WPAI was more impaired with greater depression
severity (Fig. 3a) and greater perceived cognitive dysfunction
(Fig. 3b).
The EQ-5D mean utility index score reﬂecting patients' as-
sessment of their quality of life was 0.72670.192. Quality of life
was lower in patients with greater depression severity (Fig. 4a)
and greater perceived cognitive dysfunction (Fig. 4b).
3.3. Factors associated with functioning outcomes and quality of life
Based on univariate analyses, greater functional disability,
higher work impairment and poorer quality of life were all asso-
ciated with more severe depression as measured by MADRS
(po0.001 for the association with functional disability; po0.01
for absenteeism, po0.001 for all other WPAI scores and po0.001
for quality of life). They were also all associated with more severe
perceived cognitive dysfunction (po0.001 for the association with
functional disability; po0.05 for absenteeism, po0.001 for all
other WPAI scores and po0.001 for quality of life).
In the multivariate analysis models (Table 3), greater functional
disability (SDS) remained associated with more severe depression
(MADRS) and perceived cognitive dysfunction (PDQ-D). Additionally,
a)
b)
Fig. 2. Functional disability (SDS total score) categorized by (a) severity of de-
pression (MADRS), (b) severity of perceived cognitive dysfunction (PDQ-D).
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disability: younger age, regions in South Korea outside of Seoul, and a
history of sick leave within the previous 12 months.
Greater activity impairment (WPAI) was associated with
younger patients, more severe depression (MADRS) and more se-
vere perceived cognitive dysfunction (PDQ-D) (Table 3). Greater
overall work productivity loss (WPAI) was associated with gender
(men had more impairment than women), the presence of at least
one anxiety disorder and more severe perceived cognitive dys-
function. Higher absenteeism was associated with a switch of
antidepressant at the study visit, the presence of at least one
chronic comorbid medical condition and a history of sick leave
within the previous 12 months. More severe perceived cognitive
dysfunction was the only factor signiﬁcantly associated with
higher presenteeism.
Poorer quality of life was associated with a history of sick leave
within the previous 12 months, the presence of chronic pain or
ﬁbromyalgia, more severe depression (MADRS) and more severe
perceived cognitive dysfunction (PDQ-D) (Table 3).4. Discussion
This study describes the burden of MDD on patients in South
Korea initiating or switching antidepressant monotherapy. Patients in
the study reported marked disruption across all domains of func-
tioning (social, work and family). Greater functional disability, greater
impairment in daily activities and worse quality of life were asso-
ciated with more severe depression and worse perceived cognitive
dysfunction. In addition, irrespective of depression severity, em-
ployed patients who reported more severe cognitive dysfunction also
reported worse work-related productivity outcomes.
The level of functional disability, as measured by the SDS in our
study (with nearly half of the study population reporting markedimpairment in work, social and family activities), was comparable
to that observed in the cross-sectional, observational Study of
Aspects of Asian Depression (SAAD) (Srisurapanont et al., 2013).
Similar to PERFORM-K, the SAAD also found that MDD had the
greatest impact on the work/school domain, although there were
markedly smaller differences between each domain in PERFORM-
K than in SAAD. These results differ from an observational study in
the USA, which reported greater impairment in social/leisure ac-
tivities than in work/school or family/home activities (Kennedy
et al., 2002), perhaps reﬂecting differences between the impact of
MDD on Asian and US societies.
Similar levels of impairment were reported in the study for
overall work productivity and daily activities (52% and 58% re-
spectively), which were also consistent with reports from a com-
parable European study (PERFORM) (Saragoussi et al. manuscript
in preparation). Our study also conﬁrms previous ﬁndings that
presenteeism is a greater problem than absenteeism in patients
with MDD (Stewart et al., 2003; Sanderson and Andrews, 2006).
Patients in PERFORM-K reported an average of 20% work time
missed due to MDD (absenteeism), corresponding to a loss of
approximately 10 h in the 7 days preceding the study visit. Even
when patients were present at work (35 h in the week prior to the
study interview), almost half of their time was deemed un-
productive (presenteeism). PERFORM reported a similar pre-
senteeism index but a higher absenteeism index (Saragoussi et al.
manuscript in preparation), potentially suggesting different work
cultures: patients in South Korea may face greater pressure not to
take leave due to illness compared to patients in Europe. MDD-
related work impairment is associated with substantial costs: in a
Korean study, lost productive time accounted for 33.4% of the
working patient's average annual salary, with presenteeism cost
(USD 6429) exceeding absenteeism cost (USD 3680) (Woo et al.,
2011).
The ﬁndings that greater functional disability and impairment
in daily activities were associated with greater depression severity
and worse perceived cognitive dysfunction, even when other fac-
tors were accounted for in the multivariate analyses, were con-
sistent with the European PERFORM study (Haro et al., 2013). In
both studies, functional disability was also correlated with other
factors, including country and antidepressant therapy switch at
study entry in PERFORM, and region (non-Seoul areas of South
Korea), younger patients and a history of taking sick leave in
PERFORM-K.
Factors associated with work-related outcomes were more
varied. Severity of depression as assessed by the MADRS was not
signiﬁcantly associated with any work outcome (although the as-
sociation with presenteeism at p¼0.059 was close to the threshold
of signiﬁcance). On the other hand, more severe perceived cogni-
tive dysfunction (PDQ-D) was associated with greater overall work
productivity loss and higher presenteeism.
Greater overall work productivity loss was associated with
being male, greater perceived cognitive dysfunction and the pre-
sence of at least one anxiety symptom or disorder. Ours and a
Japanese study have shown that men report greater work pro-
ductivity loss due to emotional disorders when compared to wo-
men (Wada et al., 2013). This may reﬂect traditional gender role
expectations for Asian men, such as emotional restraint, leading to
delayed help-seeking (Oliver et al., 2005; Lindinger-Sternart, 2015;
Yu et al., 2015) and potentially more severe work disability. As
anxiety and depression are commonly comorbid with each other
(Hirschfeld, 2001), anxiety appears to play a key role in work
productivity impairment and should therefore be considered
carefully by clinicians when managing MDD patients.
Higher absenteeism was associated with a switch in anti-
depressant treatment at the study visit, presence of at least one
chronic comorbid medical condition (suggesting that sick leave
a)
b)
Fig. 3. Productivity (WPAI) categorized by (a) severity of depression (MADRS), (b) severity of perceived cognitive dysfunction (PDQ-D).
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a history of sick leave within the past year, which highlights the
recurrent nature of sick leave.
Patients' perception of health status and quality of life, mea-
sured by the EQ-5D, were not as impaired as in other studies (Woo
et al., 2014; Novick et al., 2015). Patients who reported a lower
quality of life had more severe depression (MADRS), greater per-
ceived cognitive dysfunction (PDQ-D), chronic pain or ﬁ-
bromyalgia, and a history of sick leave within the past year.
Chronic pain is itself associated with poor quality of life, with ﬁ-
bromyalgia having one of the lowest EQ-5D scores compared to
other conditions with chronic pain (Picavet and Hoeymans, 2004).
However, only a small proportion of patients in PERFORM-K re-
ported chronic pain and ﬁbromyalgia (5.4% and 0.3% respectively);
thus the EQ-5D scores in PERFORM-K primarily reﬂect the impact
of MDD on patients' perceived quality of life.
In our study, perceived cognitive dysfunction was not asso-
ciated with absenteeism, but was the only factor associated with
presenteeism when all other factors were controlled for in mul-
tivariate analyses. A previous study reported that impairment in
cognitive function, such as in decision-making, contributes to
lower performance at work (Lerner et al., 2004); this may explain
why cognitive dysfunction was associated with presenteeism in
PERFORM-K. The substantial impact of MDD on presenteeism
identiﬁed in our study emphasises the importance of assessing
cognitive dysfunction in MDD patients. This is particularly so in
light of studies that have reported the persistence of cognitive
dysfunction in the remission phase of depression (Weiland-Fiedler
et al., 2004; Hammar and Ardal, 2009), resulting in impaired social
and occupational functioning (Papakostas and Culpepper, 2015).
PERFORM-K is the ﬁrst non-interventional study in Asia to
describe cognitive dysfunction in MDD patients. Perceived cogni-
tive dysfunction was assessed using PDQ-D, a 20-itemquestionnaire adapted from the PDQ scale for multiple sclerosis
and validated in depression (Fehnel et al., 2013; Lam et al., 2013),
including in a South Korean population (Kim et al. 2016). In our
study, impairment was comparable to that of depressed US pa-
tients with cognitive dysfunction, and greater than that of de-
pressed patients without cognitive dysfunction and of non-de-
pressed populations in the US and UK (Lundbeck data on ﬁle). The
present study also conﬁrmed the results of previous studies which
reported a predominance of cognitive impairment in the domains
of planning/organisation and concentration/attention over that in
the memory domain (Lam et al., 2013).
Recent research has shown that depression severity may be a
predictor of subjective cognitive dysfunction (Misdowiak et al.,
2012). However our and a previous study (Fava et al., 2009) show
only a weak correlation between depression severity and per-
ceived cognitive dysfunction, suggesting that tools used to assess
perceived cognitive dysfunction may measure a different aspect of
depression than those used to measure depression severity. Con-
sidering that in our study perceived cognitive dysfunction was
associated with work-related outcomes, while severity of depres-
sion was not, clinicians should assess cognitive dysfunction in
their daily practice, in addition to assessing the severity of de-
pressive symptoms.
The present study has a number of strengths. Patients were
recruited from tertiary centres across South Korea, thereby re-
ﬂecting the socio-demographics and clinical proﬁle of patients
across the country, similar to that of a large, national, South
Korean cohort MDD study (CRESCEND) (Kim et al., 2011). The
cross-sectional, observational methodology was useful for
gaining a better understanding of real-life clinical practice, al-
though causal inferences that could be drawn from the study
results were limited due to uncontrollable confounding factors,
selection bias or reverse causality. The use of PROs allowed us to
J.M. Kim et al. / Psychiatry Research 239 (2016) 353–361 359gather information not captured in physician-rated instruments,
namely, the patient's perspective of living with MDD and its
impact on their lives.a)
b)
Fig. 4. Quality of life (EQ-5D) categorized by (a) severity of depression (MADRS),
(b) severity of perceived cognitive dysfunction (PDQ-D).
Table 3
Multivariate analyses (p-values) of factors associated with functional disability and prod
Functional
disability
(SDS)
Absente
(WPAI)
Forced factors
Region (Seoul or rest of South Korea) 0.004n 0.948
Age (19–29, 30–54, 55–65) 0.011n 0.965
Gender 0.151 0.253
MADRS (0–25, 26–29, 30–34, 35–60) 0.022n 0.091
Factors included if po0.10 in the univariate analysis
PDQ-D (0–12, 13–27, 28–43, 44–80) o0.001n 0.415
CGI-S (0–3, 4 only, 5–7) 0.074 n.a.
Education (no degree, elementary, above) 0.081 n.a.
MDD treatment (switch or non-switch) n.a. 0.032n
Recurrent depression episode (yes or no) n.a. n.a.
Time of previous depression episode (no previous episode,
within previous 12 months, earlier than previous 12
months)
n.a. n.a.
History of hospitalisation for depression n.a. 0.091
History of suicide attempt n.a. n.a.
At least one anxiety symptom or disorder n.a. n.a.
At least one chronic medical condition 0.456 0.030n
Chronic pain or ﬁbromyalgia n.a. n.a.
Sick leave within past 12 months 0.004n 0.007n
Time since start of MDE (r8 weeks or 48 weeks) n.a. 0.104
n.a. not applicable, corresponds to factors that were not associated with outcome in un
(unless forced into the multivariate analysis models).
n po0.05 in multivariate analyses.
nn po0.05 in univariate analyses; however, the number of patients was insufﬁcientA potential limitation of the study, however, was the assess-
ment of cognitive dysfunction using the PDQ-D, which is an as-
sessment of subjective (perceived) cognitive dysfunction, rather
than objective cognitive dysfunction as measured through neu-
ropsychological tests. The relationship between subjective and
objective cognitive dysfunction is controversial; a 2012 study
showed that while depressed patients reported both subjective
and objective cognitive dysfunction, these measures were not
correlated (Svendsen et al., 2012). This lack of correlation was also
noted at the time of treatment initiation in a recent analysis of
objective and subjective measures of cognitive dysfunction (Olsen
et al., 2015). Nevertheless, two months after treatment initiation,
subjective and objective measures of cognitive dysfunction were
correlated, although changes in subjective measures of cognition
and severity of depression were more tightly correlated than
changes in subjective and objective measures of cognition. Sub-
jective cognitive dysfunction may be inﬂuenced by a patient's
mood symptoms, especially when considering its evolution over
time, and thus may not accurately reﬂect the true extent of ob-
jective cognitive dysfunction. As such, both objective and sub-
jective measures of cognitive dysfunction provide unique, com-
plementary information and should be assessed by clinicians. The
merit of the current study, despite this limitation, is in evaluating
the importance of cognitive impairment from the perspective of
the patient and in demonstrating the impact of perceived cogni-
tive dysfunction on functional disability and productivity, regard-
less of the severity of depression.
A further limitation of the study is the recruitment only of
patients who were initiating a new anti-depressant mono-
therapy, which may somewhat limit the generalisability of
the present study results to the whole MDD population in
South Korea. In addition, patients' occupations and job-related
stress levels were not captured, which may have limited the
analysis on potential mechanisms for associations with work
impairment.uctivity.
eism Presenteeism
(WPAI)
Overall work pro-
ductivity loss
(WPAI)
Activity im-
pairment
(WPAI)
Health-related
Quality of life
(EQ-5D)
0.309 0.405 0.175 0.600
0.082 0.177 0.001n 0.263
0.109 0.023n 0.086 0.936
0.059 0.151 0.043n 0.002n
0.004n 0.015n o0.001n o0.001n
0.406 0.953 0.107 0.892
0.177 0.170 0.907 n.a.
n.a. n.a. n.a. 0.112
n.a. n.a. 0.196 n.a.
n.a. n.a. n.a. 0.603
n.a. n.a.nn n.a. n.a.
n.a. n.a. n.a. 0.108
n.a. 0.032n n.a. 0.556
n.a. n.a. n.a. n.a.
n.a. n.a. 0.206 0.007n
n.a. n.a. n.a. 0.002n
n.a. n.a. n.a. n.a.
ivariate analyses at a 10% level and therefore not tested in the multivariate models
for inclusion in multivariate model.
J.M. Kim et al. / Psychiatry Research 239 (2016) 353–361360Results of the present study add to the existing evidence base
on the substantial burden of MDD on patients, and conﬁrm and
characterise the burden speciﬁcally in the South Korean popula-
tion. A lower quality of life was associated with worse depression
severity and greater perceived cognitive dysfunction. Cognitive
and depressive symptoms in MDD contribute to impaired func-
tional abilities and work productivity, particularly presenteeism.
More speciﬁcally, greater functional disability and impairment in
daily activities were found to be associated with more severe de-
pression and worse perceived cognitive function. Interestingly,
worse perceived cognitive dysfunction was associated with greater
impairment in work productivity (speciﬁcally, higher presentee-
ism and greater overall work productivity loss), irrespective of
depression severity. This highlights the importance of recognising
perceived cognitive dysfunction in routine practice, in which the
usual goal of MDD treatment is functional recovery beyond re-
mission of clinical depressive symptoms.Role of funding source
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